论文信息 - Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study - 字舞流文

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

K. Savage | M. Shipp | A. Santoro | P. Zinzani | P. Armand | A. Younes | S. Ansell | J. Kuruvilla | J. Timmerman | M. Trněný | A. Engert | R. Ramchandren | H. Lee | G. Collins | Jonathon B. Cohen | J. Boer | J. D. de Boer | A. Sumbul | J. Cohen | M. Sacchi